SCHEMBL4447965

SCHEMBL4447965

CCCc1cc(=O)cc(OC(=O)O)o1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 4/20 0.39
EPAS1 Q99814 4/20 0.39
ABCG2 Q9UNQ0 3/20 0.39
KDM4E B2RXH2 2/20 0.36
KMT2A Q03164 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 2/20 0.33
MEN1 O00255 1/20 0.33
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
POLB P06746 3/20 0.32
RAB9A P51151 3/20 0.32
STS P08842 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
ELANE P08246 3/20 0.31
HPGD P15428 2/20 0.31
TSHR P16473 1/20 0.31
HSP90AA1 P07900 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL377105 0.78 ALOX15 (0.39) ALOX15SMN1; SMN2
SCHEMBL3332762 0.75 RAB9A (0.42) HIF1AEPAS1ABCG2KDM4EKMT2A
SCHEMBL12288144 0.72 HIF1A (0.44) HIF1AEPAS1ABCG2KDM4EKMT2A
SCHEMBL6968831 0.67 KMT2A (0.41) KMT2AALDH1A1HSD17B10MEN1MAPT
SCHEMBL19182829 0.67 POLB (0.37) KDM4EALDH1A1HSD17B10MAPTPOLB
SCHEMBL4441103 0.67 PTPN1 (0.34) KDM4EKMT2AALDH1A1HSD17B10POLB
SCHEMBL10509864 0.66 PDE5A (0.39) KDM4EKMT2AALDH1A1HSD17B10MEN1
SCHEMBL17200012 0.66 PPARA (0.41) KDM4EALDH1A1HSD17B10MAPTPOLB
SCHEMBL10506675 0.65 PDE5A (0.36) KDM4EKMT2AALDH1A1HSD17B10MEN1
SCHEMBL31266381 0.65 MAPT (0.45) KDM4EKMT2AALDH1A1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120923-B1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI SA (FR) 2012-07-18 EP disclosed
EP-2120923-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME Sanofi-Aventis (FR) 2009-11-25 EP disclosed
WO-2008086949-A1 USE OF SUBSTITUTED PYRANONE ACID DERIVATIVES FOR THE TREATMENT OF METABOLIC SYNDROME SANOFI-AVENTIS (FR) 2008-07-24 WO disclosed